A Phase 2 interventional study of Pembrolizumab and Acalabrutinib in Carcinoma, Non-Small-Cell Lung, sponsored by Acerta Pharma BV. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-12.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca — 25 open to participants now, 78 under way, 28 of them phase 3. Carcinoma, Non-Small-Cell Lung · AstraZeneca.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 91st largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2015, is one of 38 in phase 2, and was the 75th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →25 of the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
AstraZeneca · Sites in Australia, Georgia, Poland and 2 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
209 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 46 · Phase 2 48 · Phase 3 44 · Phase 4 10
First in 2000; this study’s year is marked. 14 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 152 across the 137 interventional studies, 350 across the 67 observational. Of the 123 that completed or were terminated, 45 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
16 of the studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05221840Phase 3AstraZenecaA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer | 2027-01-08 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT05120349Phase 3AstraZenecaA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | 2027-08-02 |
| NCT05687266Phase 3AstraZenecaPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | 2027-11-01 |
| NCT05456867AstraZenecaA Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia | 2026-11-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pembrolizumab alone and in combination with acalabrutinib in subjects with advanced non-small cell lung cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
pembrolizumab
Drug: Pembrolizumab
acalabrutinib plus pembrolizumab
Drug: Pembrolizumab · Drug: Acalabrutinib
Also known as: Keytruda
Also known as: ACP-196
Number of Participants With Overall Response
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: Every 12 weeks for up to 2 years
| Milestone | Arm 1 - Pembrolizumab Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab |
|---|---|---|
| Started | 38 | 36 |
| Enrolled | 38 | 36 |
| Received study medication | 33 | 35 |
| Discontinued study | 38 | 36 |
| Completed | 0 | 0 |
| Not completed | 38 | 36 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
| Participants | Arm 1 - Pembrolizumab Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab |
|---|---|---|
| Number of Participants With Overall Response | 4 | 4 |
Collected over Safety Analysis tracked from 0 day to 2 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 - Pembrolizumab Monotherapy | 18/33 (54.5%) | 12/33 (36.4%) | 33/33 (100%) |
| Arm 2 - Acalabrutinib + Pembrolizumab | 23/35 (65.7%) | 18/35 (51.4%) | 35/35 (100%) |
| Event | Arm 1 - Pembrolizumab Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab |
|---|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/33 | 4/35 |
| PneumoniaInfections and infestations | 1/33 | 3/35 |
| DysphagiaGastrointestinal disorders | 2/33 | 1/35 |
| DehydrationMetabolism and nutrition disorders | 2/33 | 1/35 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 2/33 | 1/35 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 2/33 | 0/35 |
| AnaemiaBlood and lymphatic system disorders | 1/33 | 1/35 |
| Gastrointestinal HaemorrhageGastrointestinal disorders | 1/33 | 0/35 |
| Large Intestine HaemorrhageGastrointestinal disorders | 1/33 | 0/35 |
| StomatitisGastrointestinal disorders | 1/33 | 0/35 |
| Event | Arm 1 - Pembrolizumab Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab |
|---|---|---|
| FatigueGeneral disorders | 15/33 | 9/35 |
| VomitingGastrointestinal disorders | 3/33 | 13/35 |
| NauseaGastrointestinal disorders | 5/33 | 12/35 |
| Decreased AppetiteMetabolism and nutrition disorders | 6/33 | 12/35 |
| DiarrheaGastrointestinal disorders | 7/33 | 11/35 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/33 | 11/35 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/33 | 10/35 |
| AnaemiaBlood and lymphatic system disorders | 5/33 | 9/35 |
| ConstipationGastrointestinal disorders | 3/33 | 7/35 |
| Oedema PeripheralGeneral disorders | 5/33 | 7/35 |
| Age, Continuous(years) | Arm 1 - Pembrolizumab Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| Mean | 63.7 ± 10.2 | 64.6 ± 9.33 | 64.2 ± 9.70 |
| Sex: Female, Male(Participants) | Arm 1 - Pembrolizumab Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| Female | 15 | 20 | 35 |
| Male | 18 | 15 | 33 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1 - Pembrolizumab Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 32 | 34 | 66 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm 1 - Pembrolizumab Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 4 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 4 | 8 |
| White | 25 | 27 | 52 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Region of Enrollment(participants) | Arm 1 - Pembrolizumab Monotherapy | Arm 2 - Acalabrutinib + Pembrolizumab | Total |
|---|---|---|---|
| United States | 33 | 35 | 68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2015 to primary completion in Mar 2018, 34 months.
Results were first posted in Sep 2019, 1 year 6 months after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 34 months is close to that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib
Carcinoma, Non-Small-Cell Lung →